Eli Lilly announced on Tuesday that it is partnering with NVIDIA to create a supercomputer aimed at expediting drug discovery and reducing development timelines, thereby allowing the company to provide medications to patients more swiftly
Alembic Pharmaceuticals Limited (Alembic) declares that it has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ticagrelor Tablets, 60 mg.
The fifth edition of the Pink Mela - a unique and vibrant event dedicated to raising awareness about breast cancer, brought together entertainment and education for women in Nashik. Organized jointly by HCG Manavata Cancer Centre (HCGMCC) and...
Akums Drugs & Pharmaceuticals Ltd. has commenced the construction of its first global manufacturing facility in Zambia, representing a significant advancement in its international expansion efforts. The ceremonial groundbreaking was initiated...
In an exclusive interview with Thiruamuthan, Assistant Editor of India Pharma Outlook, Jordan Kohlbeck, Head of Pharmaceuticals at IAG Cargo, discusses how India’s growing role as a global pharmaceutical exporter is driving transformation in the air
Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, is presenting preclinical data on RVU305
IOL Chemicals & Pharmaceuticals Limited (IOLCP) is proud to announce an important milestone in their pharmaceutical division after being awarded a Certificate of Suitability
Sai Life Sciences Limited, among India's fastest growing Contract Research, Development and Manufacturing Organizations (CRDMO), is announcing the ground breaking of a CMC Process R&D Center at its integrated R&D campus in Hyderabad...
Bayosthiti AI, an innovator in AI-driven healthcare and molecular diagnostics, announced a strategic partnership with Narayana Health, one of the world's largest cardiac care networks, to develop AI models that predict cardiovascular disease in India
Health Canada has issued a Notice of Compliance (NOC) to Zydus Lifesciences Limited for their generic 1000 mg mesalamine suppositories